CVA Family Office LLC Makes New Investment in Cencora, Inc. (NYSE:COR)

CVA Family Office LLC bought a new stake in shares of Cencora, Inc. (NYSE:CORFree Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 139 shares of the company’s stock, valued at approximately $34,000.

Other institutional investors and hedge funds have also recently modified their holdings of the company. NBC Securities Inc. bought a new position in Cencora during the first quarter valued at $976,000. Cullen Investment Group LTD. purchased a new stake in shares of Cencora during the 1st quarter valued at about $924,000. Vanguard Group Inc. bought a new position in shares of Cencora in the 4th quarter valued at about $4,212,508,000. Czech National Bank purchased a new position in Cencora in the first quarter worth about $7,079,000. Finally, Wahed Invest LLC bought a new stake in Cencora during the fourth quarter worth approximately $567,000. 97.52% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, COO Robert P. Mauch sold 57,564 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the sale, the chief operating officer now directly owns 24,412 shares of the company’s stock, valued at $5,739,017.08. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, COO Robert P. Mauch sold 57,564 shares of the business’s stock in a transaction dated Monday, April 15th. The stock was sold at an average price of $235.09, for a total value of $13,532,720.76. Following the completion of the transaction, the chief operating officer now owns 24,412 shares of the company’s stock, valued at approximately $5,739,017.08. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Steven H. Collis sold 10,754 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $237.48, for a total value of $2,553,859.92. Following the sale, the chief executive officer now directly owns 285,088 shares in the company, valued at $67,702,698.24. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 1,956,675 shares of company stock worth $422,352,056. Company insiders own 15.80% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on COR shares. Leerink Partnrs reaffirmed an “outperform” rating on shares of Cencora in a research note on Monday, February 26th. StockNews.com downgraded Cencora from a “strong-buy” rating to a “buy” rating in a research report on Thursday, May 2nd. SVB Leerink began coverage on shares of Cencora in a research report on Monday, February 26th. They set an “outperform” rating and a $261.00 price objective on the stock. Robert W. Baird raised their target price on shares of Cencora from $275.00 to $277.00 and gave the stock an “outperform” rating in a report on Thursday, May 2nd. Finally, Citigroup upped their price target on shares of Cencora from $265.00 to $280.00 and gave the company a “buy” rating in a report on Tuesday, April 30th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $233.90.

Get Our Latest Stock Report on Cencora

Cencora Trading Up 0.4 %

COR stock opened at $236.68 on Friday. The company has a market capitalization of $47.21 billion, a PE ratio of 25.89, a P/E/G ratio of 1.64 and a beta of 0.48. The company has a debt-to-equity ratio of 3.41, a current ratio of 0.89 and a quick ratio of 0.53. Cencora, Inc. has a 12 month low of $171.65 and a 12 month high of $246.75. The firm’s 50-day moving average is $229.50 and its 200 day moving average is $226.72.

Cencora (NYSE:CORGet Free Report) last posted its quarterly earnings results on Wednesday, May 1st. The company reported $3.80 earnings per share for the quarter, beating the consensus estimate of $3.65 by $0.15. The firm had revenue of $68.41 billion during the quarter, compared to the consensus estimate of $70.60 billion. Cencora had a net margin of 0.67% and a return on equity of 268.67%. The company’s revenue was up 7.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $3.50 earnings per share. On average, research analysts anticipate that Cencora, Inc. will post 13.44 EPS for the current year.

Cencora Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, May 24th. Stockholders of record on Friday, May 10th were given a dividend of $0.51 per share. This represents a $2.04 dividend on an annualized basis and a dividend yield of 0.86%. The ex-dividend date was Thursday, May 9th. Cencora’s payout ratio is 22.32%.

Cencora Company Profile

(Free Report)

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.

Further Reading

Want to see what other hedge funds are holding COR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cencora, Inc. (NYSE:CORFree Report).

Institutional Ownership by Quarter for Cencora (NYSE:COR)

Receive News & Ratings for Cencora Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cencora and related companies with MarketBeat.com's FREE daily email newsletter.